MARKET

SYRS

SYRS

Syros Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.20
-0.33
-5.97%
After Hours: 5.21 +0.01 +0.19% 17:40 05/07 EDT
OPEN
5.86
PREV CLOSE
5.53
HIGH
5.86
LOW
5.18
VOLUME
980.50K
TURNOVER
--
52 WEEK HIGH
15.65
52 WEEK LOW
5.07
MARKET CAP
321.62M
P/E (TTM)
-2.8704
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 10h ago
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday.
Benzinga · 16h ago
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
Zacks · 1d ago
Syros Pharmaceuticals Q1 EPS $(0.23) Beats $(0.46) Estimate, Sales $4.83M Beat $2.67M Estimate
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.46) by 50 percent. This is a 41.03 percent increase over losses of $(0.39) per share
Benzinga · 1d ago
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 1d ago
BRIEF-Syros Reports Q1 Loss Per Share Of $0.23
reuters.com · 1d ago
Syros Pharmaceuticals EPS beats by $0.24, beats on revenue
Syros Pharmaceuticals (SYRS): Q1 GAAP EPS of -$0.23 beats by $0.24.Revenue of $4.83M (+102.9% Y/Y) beats by $2.16M.Shares +2.55% PM.Press Release
Seekingalpha · 1d ago
Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the...
BusinessWire - BZX · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYRS. Analyze the recent business situations of Syros Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYRS stock price target is 16.57 with a high estimate of 20.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 129
Institutional Holdings: 58.69M
% Owned: 94.90%
Shares Outstanding: 61.85M
TypeInstitutionsShares
Increased
36
2.28M
New
25
13.12M
Decreased
29
3.54M
Sold Out
16
1.11M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Nancy Simonian
Chief Financial Officer
Joseph Ferra
Chief Scientific Officer
Eric Olson
Chief Accounting Officer
Colleen DeSimone
Other
Gerald Quirk
Other
David Roth
Other
Jeremy Springhorn
Director
S. Gail Eckhardt
Director
Richard Young
Independent Director
Srinivas Akkaraju
Independent Director
Mark Alles
Independent Director
Marsha Fanucci
Independent Director
Amir Nashat
Independent Director
Phillip Sharp
No Data
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.